APA (7th ed.) Citation

N, M., D, P., R, R., E, K., R, G., L, M., . . . K, F. (2026). Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer. European urology oncology, 9(2), 240. https://doi.org/10.1016/j.euo.2025.02.015

Chicago Style (17th ed.) Citation

N, Matsubara, et al. "Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer." European Urology Oncology 9, no. 2 (2026): 240. https://doi.org/10.1016/j.euo.2025.02.015.

MLA (9th ed.) Citation

N, Matsubara, et al. "Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer." European Urology Oncology, vol. 9, no. 2, 2026, p. 240, https://doi.org/10.1016/j.euo.2025.02.015.